Clinical efficacy of imipenem/cilastatin sodium for respiratory infections in patients with lung cancer

Mlnoru Yoshida; Kentaro Watanabe; Hldeki Tanaka; Syoji Senju; Tsuneo Ishibashi; Masahiro Takamoto; Kotaro Olzumi; Yumiko Kondo; Hlromichi Shigematsu; Takayoshi Ohno; Yoichiro Ichikawa; Nobuyuki Hara; Takashi Mitsuyama; Yoichi Nakanishi; Hozumi Yamada; Shigetaka Kuroki; Akira Motohiro; Hitoshi Ueda; Takuo Kusano; Masafumi Hiratsuka; Yoshihiko Nikaido; Masamitsu Kido; Tomoko Mlyahara; Klyoshi Nlnomiya; Yoshikazu Matsuzaki; Nobuyoshi Mlyazaki; Yukito Ichinose; Tokujiro Yano; Elji Tarai; Takashi Inoue; Hlroshi Aso; Hironori Takihara; Fumihiko Maeda; Kazuyuki Higuchi; Masato Kato; Sadanori Takeo; Yukio Kurita; Atsushi Yano; Yoshiyuki Matsumoto; O. E. Toshiyuki; Tomokazu Zaizen; Koji Namba; Hiroaki Naoe

Clinical efficacy of imipenem/cilastatin sodium for respiratory infections in patients with lung cancer

Mlnoru Yoshida, Kentaro Watanabe, Hldeki Tanaka, Syoji Senju, Tsuneo Ishibashi, Masahiro Takamoto, Kotaro Olzumi, Yumiko Kondo, Hlromichi Shigematsu, Takayoshi Ohno, Yoichiro Ichikawa, Nobuyuki Hara, Takashi Mitsuyama, Yoichi Nakanishi, Hozumi Yamada, Shigetaka Kuroki, Akira Motohiro, Hitoshi Ueda, Takuo Kusano, Masafumi HiratsukaYoshihiko Nikaido, Masamitsu Kido, Tomoko Mlyahara, Klyoshi Nlnomiya, Yoshikazu Matsuzaki, Nobuyoshi Mlyazaki, Yukito Ichinose, Tokujiro Yano, Elji Tarai, Takashi Inoue, Hlroshi Aso, Hironori Takihara, Fumihiko Maeda, Kazuyuki Higuchi, Masato Kato, Sadanori Takeo, Yukio Kurita, Atsushi Yano, Yoshiyuki Matsumoto, O. E. Toshiyuki, Tomokazu Zaizen, Koji Namba, Hiroaki Naoe

Department of Respirology

Research output: Contribution to journal › Article › peer-review

Abstract

Imipenem/cilastatin sodium (IPM/CS) was administered to 102 patients with respiratory tract infections and lung cancer. Patients with other serious diseases were excluded and a total of 73 patients were enrolled. They were divided into 12 patients who underwent surgery (operated group) and 61 who did not (non-operated group); the latter group included 28 patients treated with anticancer agents or radiation therapy (treated group) and 33 untreated patients (untreated group). IPM/CS was effective in 75% of the patients, both with and without surgery. The drug was effective in 81% of the treated group, although many of the patients had Stage III or more advanced cancer, as well as bronchial occlusion. IPM/CS was also effective in 69% of the untreated group, although many of the patients have serious infections and a PS (Performance Status) of 3 or greater. Thus, IPM/CS treatment achieved good results. Bacteriological studies showed that 3 out of 4 strains in the operated group and 16 out of 18 in the non-operated group were eliminated. Safety was evaluated in all patients. Two patients (2%) experienced side effects and two others (2%) showed abnormal clinical findings, but the symptoms were mild and resolved after discontinuation or completion of therapy. In conclusion, IPM/CS was very effective for treating respiratory infections in patients with lung cancer.

Original language	English
Pages (from-to)	36-38
Number of pages	3
Journal	Japanese Journal of Antibiotics
Volume	50
Issue number	1
Publication status	Published - 1997

All Science Journal Classification (ASJC) codes

Microbiology (medical)
Pharmacology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Yoshida, M., Watanabe, K., Tanaka, H., Senju, S., Ishibashi, T., Takamoto, M., Olzumi, K., Kondo, Y., Shigematsu, H., Ohno, T., Ichikawa, Y., Hara, N., Mitsuyama, T., Nakanishi, Y., Yamada, H., Kuroki, S., Motohiro, A., Ueda, H., Kusano, T., ... Naoe, H. (1997). Clinical efficacy of imipenem/cilastatin sodium for respiratory infections in patients with lung cancer. Japanese Journal of Antibiotics, 50(1), 36-38.

Yoshida, M, Watanabe, K, Tanaka, H, Senju, S, Ishibashi, T, Takamoto, M, Olzumi, K, Kondo, Y, Shigematsu, H, Ohno, T, Ichikawa, Y, Hara, N, Mitsuyama, T, Nakanishi, Y, Yamada, H, Kuroki, S, Motohiro, A, Ueda, H, Kusano, T, Hiratsuka, M, Nikaido, Y, Kido, M, Mlyahara, T, Nlnomiya, K, Matsuzaki, Y, Mlyazaki, N, Ichinose, Y, Yano, T, Tarai, E, Inoue, T, Aso, H, Takihara, H, Maeda, F, Higuchi, K, Kato, M, Takeo, S, Kurita, Y, Yano, A, Matsumoto, Y, Toshiyuki, OE, Zaizen, T, Namba, K & Naoe, H 1997, 'Clinical efficacy of imipenem/cilastatin sodium for respiratory infections in patients with lung cancer', Japanese Journal of Antibiotics, vol. 50, no. 1, pp. 36-38.

@article{afd19893e264493daa7a257f8e7d9374,

title = "Clinical efficacy of imipenem/cilastatin sodium for respiratory infections in patients with lung cancer",

abstract = "Imipenem/cilastatin sodium (IPM/CS) was administered to 102 patients with respiratory tract infections and lung cancer. Patients with other serious diseases were excluded and a total of 73 patients were enrolled. They were divided into 12 patients who underwent surgery (operated group) and 61 who did not (non-operated group); the latter group included 28 patients treated with anticancer agents or radiation therapy (treated group) and 33 untreated patients (untreated group). IPM/CS was effective in 75% of the patients, both with and without surgery. The drug was effective in 81% of the treated group, although many of the patients had Stage III or more advanced cancer, as well as bronchial occlusion. IPM/CS was also effective in 69% of the untreated group, although many of the patients have serious infections and a PS (Performance Status) of 3 or greater. Thus, IPM/CS treatment achieved good results. Bacteriological studies showed that 3 out of 4 strains in the operated group and 16 out of 18 in the non-operated group were eliminated. Safety was evaluated in all patients. Two patients (2%) experienced side effects and two others (2%) showed abnormal clinical findings, but the symptoms were mild and resolved after discontinuation or completion of therapy. In conclusion, IPM/CS was very effective for treating respiratory infections in patients with lung cancer.",

author = "Mlnoru Yoshida and Kentaro Watanabe and Hldeki Tanaka and Syoji Senju and Tsuneo Ishibashi and Masahiro Takamoto and Kotaro Olzumi and Yumiko Kondo and Hlromichi Shigematsu and Takayoshi Ohno and Yoichiro Ichikawa and Nobuyuki Hara and Takashi Mitsuyama and Yoichi Nakanishi and Hozumi Yamada and Shigetaka Kuroki and Akira Motohiro and Hitoshi Ueda and Takuo Kusano and Masafumi Hiratsuka and Yoshihiko Nikaido and Masamitsu Kido and Tomoko Mlyahara and Klyoshi Nlnomiya and Yoshikazu Matsuzaki and Nobuyoshi Mlyazaki and Yukito Ichinose and Tokujiro Yano and Elji Tarai and Takashi Inoue and Hlroshi Aso and Hironori Takihara and Fumihiko Maeda and Kazuyuki Higuchi and Masato Kato and Sadanori Takeo and Yukio Kurita and Atsushi Yano and Yoshiyuki Matsumoto and Toshiyuki, {O. E.} and Tomokazu Zaizen and Koji Namba and Hiroaki Naoe",

year = "1997",

language = "English",

volume = "50",

pages = "36--38",

journal = "Japanese Journal of Antibiotics",

issn = "0368-2781",

publisher = "Japan Antibiotics Research Association",

number = "1",

}

TY - JOUR

T1 - Clinical efficacy of imipenem/cilastatin sodium for respiratory infections in patients with lung cancer

AU - Yoshida, Mlnoru

AU - Watanabe, Kentaro

AU - Tanaka, Hldeki

AU - Senju, Syoji

AU - Ishibashi, Tsuneo

AU - Takamoto, Masahiro

AU - Olzumi, Kotaro

AU - Kondo, Yumiko

AU - Shigematsu, Hlromichi

AU - Ohno, Takayoshi

AU - Ichikawa, Yoichiro

AU - Hara, Nobuyuki

AU - Mitsuyama, Takashi

AU - Nakanishi, Yoichi

AU - Yamada, Hozumi

AU - Kuroki, Shigetaka

AU - Motohiro, Akira

AU - Ueda, Hitoshi

AU - Kusano, Takuo

AU - Hiratsuka, Masafumi

AU - Nikaido, Yoshihiko

AU - Kido, Masamitsu

AU - Mlyahara, Tomoko

AU - Nlnomiya, Klyoshi

AU - Matsuzaki, Yoshikazu

AU - Mlyazaki, Nobuyoshi

AU - Ichinose, Yukito

AU - Yano, Tokujiro

AU - Tarai, Elji

AU - Inoue, Takashi

AU - Aso, Hlroshi

AU - Takihara, Hironori

AU - Maeda, Fumihiko

AU - Higuchi, Kazuyuki

AU - Kato, Masato

AU - Takeo, Sadanori

AU - Kurita, Yukio

AU - Yano, Atsushi

AU - Matsumoto, Yoshiyuki

AU - Toshiyuki, O. E.

AU - Zaizen, Tomokazu

AU - Namba, Koji

AU - Naoe, Hiroaki

PY - 1997

Y1 - 1997

N2 - Imipenem/cilastatin sodium (IPM/CS) was administered to 102 patients with respiratory tract infections and lung cancer. Patients with other serious diseases were excluded and a total of 73 patients were enrolled. They were divided into 12 patients who underwent surgery (operated group) and 61 who did not (non-operated group); the latter group included 28 patients treated with anticancer agents or radiation therapy (treated group) and 33 untreated patients (untreated group). IPM/CS was effective in 75% of the patients, both with and without surgery. The drug was effective in 81% of the treated group, although many of the patients had Stage III or more advanced cancer, as well as bronchial occlusion. IPM/CS was also effective in 69% of the untreated group, although many of the patients have serious infections and a PS (Performance Status) of 3 or greater. Thus, IPM/CS treatment achieved good results. Bacteriological studies showed that 3 out of 4 strains in the operated group and 16 out of 18 in the non-operated group were eliminated. Safety was evaluated in all patients. Two patients (2%) experienced side effects and two others (2%) showed abnormal clinical findings, but the symptoms were mild and resolved after discontinuation or completion of therapy. In conclusion, IPM/CS was very effective for treating respiratory infections in patients with lung cancer.

AB - Imipenem/cilastatin sodium (IPM/CS) was administered to 102 patients with respiratory tract infections and lung cancer. Patients with other serious diseases were excluded and a total of 73 patients were enrolled. They were divided into 12 patients who underwent surgery (operated group) and 61 who did not (non-operated group); the latter group included 28 patients treated with anticancer agents or radiation therapy (treated group) and 33 untreated patients (untreated group). IPM/CS was effective in 75% of the patients, both with and without surgery. The drug was effective in 81% of the treated group, although many of the patients had Stage III or more advanced cancer, as well as bronchial occlusion. IPM/CS was also effective in 69% of the untreated group, although many of the patients have serious infections and a PS (Performance Status) of 3 or greater. Thus, IPM/CS treatment achieved good results. Bacteriological studies showed that 3 out of 4 strains in the operated group and 16 out of 18 in the non-operated group were eliminated. Safety was evaluated in all patients. Two patients (2%) experienced side effects and two others (2%) showed abnormal clinical findings, but the symptoms were mild and resolved after discontinuation or completion of therapy. In conclusion, IPM/CS was very effective for treating respiratory infections in patients with lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=20244383712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244383712&partnerID=8YFLogxK

M3 - Article

C2 - 9059911

AN - SCOPUS:20244383712

SN - 0368-2781

VL - 50

SP - 36

EP - 38

JO - Japanese Journal of Antibiotics

JF - Japanese Journal of Antibiotics

IS - 1

ER -

Clinical efficacy of imipenem/cilastatin sodium for respiratory infections in patients with lung cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this